GLP-1 Investing Hub 2026: Eli Lilly, Novo Nordisk, Oral Pills, Compounding & Supply-Chain Stocks
.png)
Home › Pharma › GLP-1 Investing Hub By OneDayAdvisor Editorial Team | Published: October 14, 2026 | Last updated: November 2026 (company results through Novo Nordisk’s Nov 4 report) QUICK ANSWER GLP-1 investing in November 2026 turns on volume growth against falling prices. Lilly’s Q3 revenue rose 39% to $24.4 billion and its 2026 guidance rose to $91–92 billion; Novo’s adjusted sales rose 4%, led by the Wegovy pill (DKK 5.39 billion), and its outlook now spans −2% to +2%. The key questions are valuation, price erosion, Medicare policy and pipeline timing, including CagriSema’s FDA decision and retatrutide’s 2027 filing, not whether demand exists. [1] [2] Disclosure. This article is educational research, not investment, tax or medical advice. OneDayAdvisor is not a registered investment adviser, and n...